Deciphering the binding of Caveolin-1 to client protein endothelial nitric-oxide synthase (eNOS): Scaffolding subdomain identification, interaction modeling, and biological significance

Journal of Biological Chemistry

Volumn 289, Issue 19, 2014, Pages 13273-13283

  Trane, Andy E ^a   Pavlov, Dmitri ^a   Sharma, Arpeeta ^a   Saqib, Uzma ^b   Lau, Kelvin ^a   Van Petegem, Filip ^a   Minshall, Richard D ^b   Roman, Linda J ^c   Bernatchez, Pascal N ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOCHEMISTRY; ENDOTHELIAL CELLS; NITRIC OXIDE; PROTEINS;

BIOLOGICAL SIGNIFICANCE; ENDOTHELIAL NITRIC-OXIDE SYNTHASE (ENOS); GENE INACTIVATION; INTERACTION MODEL; INTRACELLULAR DELIVERY; NITRIC-OXIDE SYNTHASE; PULMONARY COMPLICATIONS; VASCULAR ENDOTHELIAL CELLS;

SCAFFOLDS (BIOLOGY);

CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CELL TRANSPORT; COMPUTER MODEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; INTRACELLULAR SIGNALING; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE;

CAVEOLAE; CAVEOLIN; ENDOTHELIUM; NITRIC OXIDE; NITRIC-OXIDE SYNTHASE;

AMINO ACID SUBSTITUTION; ANIMALS; CATTLE; CAVEOLIN 1; CELLS, CULTURED; COMPUTER SIMULATION; ENDOTHELIAL CELLS; HUMANS; MODELS, MOLECULAR; MUTATION, MISSENSE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN BINDING;

EID: 84900447254     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.528695     Document Type: Article

References (56)

1. Frank, P. G., Lee, H., Park, D. S., Tandon, N. N., Scherer, P. E., and Lisanti, M. P. (2004) Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 98-105
2. Minshall, R. D., Tiruppathi, C., Vogel, S. M., and Malik, A. B. (2002) VeseNOS icle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem. Cell Biol. 117, 105-112
3. Yu, J., Bergaya, S., Murata, T., Alp, I. F., Bauer, M. P., Lin, M. I., Drab, M., Kurzchalia, T. V., Stan, R. V., and Sessa, W. C. (2006) Direct evidence for the role of caveolin-1 and caveolae in mechano-transduction and remodeling of blood vessels. J. Clin. Invest. 116, 1284-1291
4. Gratton, J. P., Bernatchez, P., and Sessa, W. C. (2004) Caveolae and caveolins in the cardiovascular system. Circ. Res. 94, 1408-1417
5. Babak, R., Woodman, S. E., and Lisanti, M. P. (2002) Caveolae: from cell biology to animal physiology. Pharmacol. Rev. 54, 431-467
6. Drab, M., Verkade, P., Elger, M., Kasper, M., Lohn, M., Lauterbach, B., Menne, J., Lindschau, C., Mende, F., Luft, F. C., Schedl, A., Haller, H., and Kurzchalia, T. V. (2001) Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293, 2449-2452
7. Razani, B., Engelman, J. A., Wang, X. B., Schubert, W., Zhang, X. L., Marks, C. B., Macaluso, F., Russell, R. G., Li, M., Pestell, R. G., Di Vizio, D., Hou, H., Jr., Kneitz, B., Lagaud, G., Christ, G. J., Edelmann, W., and Lisanti, M. P. (2001) Caveolin-1-null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276, 38121-38138
8. Murata, T., Lin, M. I., Huang, Y., Yu, J., Bauer, P. M., Giordano, F. J., and Sessa, W. C. (2007) Reexpression of caveolin-1 in endothelium rescues the vascular, cardiac, and pulmonary defects in global caveolin-1 knockout mice. J. Exp. Med. 204, 2373-2382
9. Lin, M. I., Yu, J., Murata, T., and Sessa, W. C. (2007) Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res. 67, 2849-2856
10. Fernández-Hernando, C., Yu, J., Suárez, Y., Rahner, C., Dávalos, A., Lasunción, M. A., and Sessa, W. C. (2009) Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab. 10, 48-54
11. -/- mice. Am. J. Physiol. Lung Cell Mol. Physiol. 294, L865-873
12. Yamamoto, M., Toya, Y., Jensen, R. A., and Ishikawa, Y. (1999) Caveolin is an inhibitor of platelet-derived growth factor receptor signaling. Exp. Cell Res. 247, 380-388
13. Razani, B., Rubin, C. S., and Lisanti, M. P. (1999) Regulation of cAMPmediated signal transduction via interaction of caveolins with the catalytic subunit of protein kinase A. J. Biol. Chem. 274, 26353-26360
14. Hagiwara, M., Shirai, Y., Nomura, R., Sasaki, M., Kobayashi, K., Tadokoro, T., and Yamamoto, Y. (2009) Caveolin-1 activates Rab5 and enhances endocytosis through direct interaction. Biochem. Biophys. Res. Commun. 378, 73-78
15. García-Cardeña, G., Martasek, P., Masters, B. S., Skidd, P. M., Couet, J., Li, S., Lisanti, M. P., and Sessa, W. C. (1997) Dissecting the interaction between nitric-oxide synthase (NOS) and caveolin. J. Biol. Chem. 272, 25437-25440
16. Griffith, T. M, Edwards, D. H., Lewis, M. J., Newby, A. C., and Henderson, A. H. (1984) The nature of endothelium-derived vascular relaxant factor. Nature 308, 645-647
17. García-Cardeña, G., Oh, P., Liu, J., Schnitzer, J. E., and Sessa, W. C. (1996) Targeting of nitric-oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc. Natl. Acad. Sci. U. S. A. 93, 6448-6453
18. Ju, H., Zou, R., Venema, V. J., and Venema, R. C. (1997) Direct interaction of endothelial nitric-oxide synthase and caveolin-1 inhibits synthase activity. J. Biol. Chem. 272, 18522-18525
19. 2+-calmodulin and caveolin. J. Biol. Chem. 272, 15583-15586
20. García-Cardeña, G., Fan, R., Stern, D. F., Liu, J., and Sessa, W. C. (1996) Endothelial nitric-oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem. 271, 27237-27240
21. Gratton, J. P., Fontana, J., O'Connor, D. S., Garcia-Cardena, G., McCabe, T. J., and Sessa, W. C. (2000) Reconstitution of an endothelial nitric-oxide synthase (eNOS), Hsp90, and caveolin-1 complex in vitro. J. Biol. Chem. 275, 22268-22272
22. Chen, Z., Bakhshi, F. R., Shajahan, A. N., Sharma, T., Mao, M., Trane, A., Bernatchez, P., Van Nieuw Amerongen, G. P., Bonini, M. G., Skidgel, R. A., Malik, A. B., and Minshall, R. D. (2012) Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition. Mol. Biol. Cell 23, 1388-1398
23. Landmesser, U., Burkhard, H., and Drexler, H. (2004) Endothelial function: a critical determinant in atherosclerosis? Circulation 109, S27-33
24. Archer, S. L., and Michelakis, E. D. (2009) Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension. New Engl. J. Med. 361, 1864-1871
25. Nadar, S., Blann, A. D., and Lip, G. Y. (2004) Endothelial dysfunction: methods of assessment and application to hypertension. Curr. Pharm. Des. 10, 3591-3605
26. Sitia, S., Tomasoni, L., Atzeni, F., Ambrosio, G., Cordiano, C., Catapano, A., Tramontana, S., Perticone, F., Naccarato, P., Camici, P., Picano, E., Cortigiani, L., Bevilacqua, M., Milazzo, L., Cusi, D., Barlassina, C., Sarzi-Puttini, P., and Turiel, M. (2010) From endothelial dysfunction to atherosclerosis. Autoimmune Rev. 9, 830-834
27. Taddei, S., Virdis, A., Ghiadoni, L., Sudano, I., and Salvetti, A. (2000) Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr. Hypertens. Rep. 2, 64-70
28. Shesely, E. G., Maeda, N., Kim, H. S., Desai, K. M., Krege, J. H., Laubach, V. E., Sherman, P. A., Sessa, W. C., and Smithies, O. (1996) Elevated blood pressures in mice lacking endothelial nitric-oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 93, 13176-13181.
29. Yang, Y. M., Huang, A., Kaley, G., and Sun, D. (2009) eNOS uncoupling and endothelial dysfunction in aged vessels. Am. J. Physiol. Heart Circ. Physiol. 297, H1829-1836
30. Zhao, Y. Y., Zhao, Y. D., Mirza, M. K., Huang, J. H., Potula, H. H., Vogel, S. M., Brovkovych, V., Yuan, J. X., Wharton, J., and Malik, A. B. (2009) Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J. Clin. Invest. 119, 2009-2018
31. -/- knock-out mice: treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1-null mice. J. Biol. Chem. 277, 40091-40098
32. Murata, T., Lin, M. I., Stan, R. V., Bauer, P. M., Yu, J., and Sessa, W. C. (2007) Genetic evidence supporting caveolae microdomain regulation of calcium entry in endothelial cells. J. Biol. Chem. 282, 16631-16643
33. Bauer, P. M., Yu, J., Chen, Y., Hickey, R., Bernatchez, P. N., Looft-Wilson, R., Huang, Y., Giordano, F., Stan, R. V., and Sessa, W. C. (2005) Endothelialspecific expression of caveolin-1 impairs microvascular permeability and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 102, 204-209
34. Bucci, M., Gratton, J. P., Rudic, R. D., Acevedo, L., Roviezzo, F., Cirino, G., and Sessa, W. C. (2000) In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6, 1362-1367
35. Bernatchez, P., Sharma, A., Bauer, P. M., Marin, E., and Sessa, W. C. (2011) A noninhibitory mutant of the caveolin-1 scaffolding domain enhances eNOS-derived NO synthesis and vasodilation in mice. J. Clin. Invest. 121, 3747-3755
36. Bernatchez, P. N., Bauer, P. M., Yu, J., Prendergast, J. S., He, P., and Sessa, W. C. (2005) Dissecting the molecular control of endothelialNOsynthase by caveolin-1 using cell-permeable peptides. Proc. Natl. Acad. Sci. U. S. A. 102, 761-766
37. Sharma, A., Trane, A., Yu, C., Jasmin, J. F., and Bernatchez, P. (2011) Amlodipine increases endothelial nitric oxide release by modulating binding of native eNOS protein complex to caveolin-1. Eur. J. Pharmacol. 659, 206-212
38. Kaplánek, R., Martásek, P., Grüner, B., Panda, S., Rak, J., Masters, B. S., Král, V., and Roman, L. J. (2012) Nitric-oxide synthases activation and inhibition by metallacarborane-cluster-based isoform-specific affectors. J. Med. Chem. 55, 9541-9548
39. Collins, B. M., Davis, M. J., Hancock, J. F., and Parton, R. G. (2012) Structure-based reassessment of the caveolin signaling model: do caveeNOS olae regulate signaling through caveolin-protein interactions? Dev. Cell 23, 11-20.
40. Bernatchez, P. N., Acevedo, L., Fernandez-Hernando, C., Murata, T., Chalouni, C., Kim, J., Erdjument-Bromage, H., Shah, V., Gratton, J. P, Mc-Nally, E. M., Tempst, P., and Sessa, W. C. (2007) Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J. Biol. Chem. 282, 30745-30753
41. Darnell, S. J., Page, D., and Mitchell, J. C. (2007) An automated decisiontree approach to predicting protein interaction hotspots. Proteins 68, 813-823
42. Zhu, X., and Mitchell, J. C. (2011) KFC2: a knowledge-based hot spot prediction method based on interface solvation, atomic density, and plasticity features. Proteins 79, 2671-2683
43. Tovchigrechko, A., and Vakser, I. A. (2006) GRAMM-X public web server for protein-protein docking. Nucleic Acids Res. 34, W310-314
44. Tovchigrechko, A., and Vakser, I. A. (2005) Development and testing of an automated approach to protein docking. Proteins 60, 296-301
45. Aoyagi, M., Arvai, A. S., Tainer, J. A., and Getzoff, E. D. (2003) Structural basis for endothelial nitric-oxide synthase binding to calmodulin. EMBOJ. 22, 766-775
46. Spisni, E., Tomasi, V., Cestaro, A., and Tosatto, S. C. (2005) Structural insights into the function of human caveolin 1. Biochem. Biophys. Res. Commun. 338, 1383-1390
47. Busconi, L., and Michel, T. (1995) Recombinant endothelial nitric-oxide synthase: post-translational modifications in a baculovirus expression system. Mol. Pharmacol. 47, 655-659
48. Rosenfeld, R. J., Garcin, E. D., Panda, K., Andersson, G., Aberg, A., Wallace, A. V., Morris, G. M., Olson, A. J., Stuehr, D. J., Tainer, J. A., and Getzoff, E. D. (2002) Conformational changes in nitric-oxide synthases induced by chlorzoxazone and nitroindazoles: crystallographic and computational analyses of inhibitor potency. Biochemistry 41, 13915-13925
49. Michel, J. B., Feron, O., Sase, K., Prabhakar, P., and Michel, T. (1997) Caveolin versus calmodulin: counterbalancing allosteric modulators of endothelial nitric-oxide synthase. J. Biol. Chem. 272, 25907-25912
50. Kuhlencordt, P. J., Gyurko, R., Han, F., Scherrer-Crosbie, M., Aretz, T. H., Hajjar, R., Picard, M. H., and Huang, P. L. (2001) Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric-oxide synthase double-knockout mice. Circulation 104, 448-454
51. Parton, R. G., Hanzal-Bayer, M., and Hancock, J. F. (2006) Biogenesis of caveolae: a structural model for caveolin-induced domain formation. J. Cell Sci. 119, 787-796
52. Fernandez, I., Ying, Y., Albanesi, J., and Anderson, R. G. (2002) Mechanism of caveolin filament assembly. Proc. Natl. Acad. Sci. U. S. A. 99, 11193-11198
53. Couet, J., Li, S., Okamoto, T., Ikezu, T., and Lisanti, M. P. (1997) Identification of peptide and protein ligands for the caveolin-scaffolding domain. J. Biol. Chem. 272, 6525-6533
54. Raman, C. S., Li, H., Martásek, P., Southan, G., Masters, B. S., and Poulos, T. L. (2001) Crystal structure of nitric-oxide synthase bound to nitroindazole reveals a novel inactivation mechanism. Biochemistry 40, 13448-13455
55. Feron, O., Belhassen, L., Kobzik, L., Smith, T. W., Kelly, R. A., and Michel, T. (1996) Endothelial nitric-oxide synthase targeting to caveolae. J. Biol. Chem. 271, 22810-22814
56. Fischmann, T. O., Hruza, A., Niu, X. D., Fossetta, J. D., Lunn, C. A., Dolphin, E., Prongay, A. J., Reichert, P., Lundell, D. J., Narula, S. K., and Weber, P. C. (1999) Structural characterization of nitric-oxide synthase isoforms reveals striking active-site conservation. Nat. Struct. Biol. 6, 233-242